Shares in Thermo Fisher Scientific do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend. Investors have an opportunity to buy the stock and target the $ 525.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
The group's high margin levels account for strong profits.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past twelve months, EPS forecast has been revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The tendency within the weekly time frame is positive above the technical support level at 350.95 USD
Based on current prices, the company has particularly high valuation levels.
The firm trades with high earnings multiples: 36.98 times its 2020 earnings per share.
The company is not the most generous with respect to shareholders' compensation.
For the past seven days, analysts have been lowering their EPS expectations for the company.
Subsector Advanced Medical Equipment & Technology - NEC
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.